| Description | DRB is a nucleoside analog that inhibits several carboxyl-terminal domain (CTD) kinases including casein kinase II (IC50 range of 4-10 μM) |
| In vitro | DRB can inhibit HIV transcription (IC50 = ~4 μM) by targeting elongation enhanced by the HIV-encoded transactivator Tat[1]. |
| Target activity | CTD:4-10 µM |
| molecular weight | 319.14 |
| Molecular formula | C12H12Cl2N2O4 |
| CAS | 53-85-0 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 3.19 mg/mL (10 mM) |
| References | 1. Marciniak R A , Sharp P A . HIV-1 Tat protein promotes formation of more-processive elongation complexes.[J]. Embo Journal, 1991, 10(13):4189-4196. 2. Zandomeni R O . Kinetics of inhibition by 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole on calf thymus casein kinase II[J]. biochemical journal, 1989, 262(2):469-473. |